Burzynski Research
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting se… Read more
Burzynski Research (BZYR) - Net Assets
Latest net assets as of November 2025: $-67.34K USD
Based on the latest financial reports, Burzynski Research (BZYR) has net assets worth $-67.34K USD as of November 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.27K) and total liabilities ($69.61K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-67.34K |
| % of Total Assets | -2973.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 563.9 |
Burzynski Research - Net Assets Trend (1998–2025)
This chart illustrates how Burzynski Research's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Burzynski Research (1998–2025)
The table below shows the annual net assets of Burzynski Research from 1998 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-02-28 | $-41.64K | -65.73% |
| 2024-02-29 | $-25.12K | -83.02% |
| 2023-02-28 | $-13.73K | -1238.23% |
| 2022-02-28 | $1.21K | +102.63% |
| 2021-02-28 | $-45.84K | +69.96% |
| 2020-02-29 | $-152.59K | +18.25% |
| 2019-02-28 | $-186.65K | -73.30% |
| 2018-02-28 | $-107.70K | -226.35% |
| 2017-02-28 | $-33.00K | +67.33% |
| 2016-02-29 | $-101.02K | +26.98% |
| 2015-02-28 | $-138.34K | +8.15% |
| 2014-02-28 | $-150.62K | -77.91% |
| 2013-02-28 | $-84.66K | -105.25% |
| 2012-02-29 | $-41.25K | +19.52% |
| 2011-02-28 | $-51.26K | -5.73% |
| 2010-02-28 | $-48.48K | +44.50% |
| 2009-02-28 | $-87.35K | -49.97% |
| 2008-02-29 | $-58.25K | -9.53% |
| 2007-02-28 | $-53.18K | -88.04% |
| 2006-02-28 | $-28.28K | -36.02% |
| 2005-02-28 | $-20.79K | +36.27% |
| 2004-02-29 | $-32.63K | -596.10% |
| 2003-02-28 | $-4.69K | -113.78% |
| 2002-02-28 | $34.00K | +18.71% |
| 2001-02-28 | $28.64K | +298.50% |
| 2000-02-29 | $-14.43K | -1958.35% |
| 1999-02-28 | $-701.00 | +99.82% |
| 1998-02-28 | $-397.33K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Burzynski Research's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9640570300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (February 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $131.45K | % |
| Other Components | $129.30 Million | % |
| Total Equity | $-41.64K | 100.00% |
Burzynski Research Competitors by Market Cap
The table below lists competitors of Burzynski Research ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AIS Resources Ltd
V:AIS
|
$1.22 Million |
|
Ortin Laboratories Limited
NSE:ORTINLAB
|
$1.22 Million |
|
Nova Net Lease REIT
PINK:NNLRF
|
$1.23 Million |
|
Riedel Resources Ltd
AU:RIE
|
$1.23 Million |
|
Sultan Resources Ltd
AU:SLZ
|
$1.22 Million |
|
Mace Security Intl
PINK:MACE
|
$1.22 Million |
|
Artea SA
PA:ARTE
|
$1.22 Million |
|
MATERION
MU:BEM
|
$1.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Burzynski Research's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -25,123 to -41,637, a change of -16,514.
- Net loss of 1,386,207 reduced equity.
- New share issuances of 388,068 increased equity.
- Other factors increased equity by 981,625.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.39 Million | -3329.27% |
| Share Issuances | $388.07K | +932.03% |
| Other Changes | $981.62K | +2357.58% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Burzynski Research's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-02-28 | $0.00 | $0.05 | x |
| 1999-02-28 | $0.00 | $0.05 | x |
| 2000-02-29 | $0.00 | $0.05 | x |
| 2001-02-28 | $0.00 | $0.05 | x |
| 2002-02-28 | $0.00 | $0.05 | x |
| 2003-02-28 | $0.00 | $0.05 | x |
| 2004-02-29 | $0.00 | $0.05 | x |
| 2005-02-28 | $0.00 | $0.05 | x |
| 2006-02-28 | $0.00 | $0.05 | x |
| 2007-02-28 | $0.00 | $0.05 | x |
| 2008-02-29 | $0.00 | $0.05 | x |
| 2009-02-28 | $0.00 | $0.05 | x |
| 2010-02-28 | $0.00 | $0.05 | x |
| 2011-02-28 | $0.00 | $0.05 | x |
| 2012-02-29 | $0.00 | $0.05 | x |
| 2013-02-28 | $0.00 | $0.05 | x |
| 2014-02-28 | $0.00 | $0.05 | x |
| 2015-02-28 | $0.00 | $0.05 | x |
| 2016-02-29 | $0.00 | $0.05 | x |
| 2017-02-28 | $0.00 | $0.05 | x |
| 2018-02-28 | $0.00 | $0.05 | x |
| 2019-02-28 | $0.00 | $0.05 | x |
| 2020-02-29 | $0.00 | $0.05 | x |
| 2021-02-28 | $0.00 | $0.05 | x |
| 2022-02-28 | $0.00 | $0.05 | x |
| 2023-02-28 | $0.00 | $0.05 | x |
| 2024-02-29 | $0.00 | $0.05 | x |
| 2025-02-28 | $0.00 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Burzynski Research utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-4008.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 0.00% | -33346.21% | 0.05x | 0.00x | $-7.09 Million |
| 1999 | 0.00% | -812528.23% | 0.00x | 0.00x | $-5.04 Million |
| 2000 | 0.00% | -9361.17% | 0.24x | 0.00x | $-4.38 Million |
| 2001 | -16035.42% | -432473.16% | 0.01x | 3.97x | $-4.60 Million |
| 2002 | -15222.51% | -172526.80% | 0.03x | 2.70x | $-5.18 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.42 Million |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.38 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.96 Million |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.60 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.30 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.52 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.12 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.83 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.03 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.15 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.49 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.26 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.88 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.99 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.50 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.60 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.62 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.62 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.20 Million |
| 2022 | -80983.08% | 0.00% | 0.00x | 3.86x | $-976.78K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-914.92K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.33 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.38 Million |
Industry Comparison
This section compares Burzynski Research's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Burzynski Research (BZYR) | $-67.34K | 0.00% | N/A | $1.22 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |